WILMINGTON, NC (NEWS RELEASE) — Pharmaceutical Product Development, LLC (PPD) today announced that its board of directors has named David Simmons chairman and CEO. Mr. Simmons, an experienced pharmaceutical industry executive, joins PPD from Pfizer Inc., where he served as president and general manager of the emerging markets and established products business units. Mr. Simmons begins his new role June 4 and will be based in PPD’s headquarters in Wilmington, N.C.
"We are pleased to welcome David to PPD," said Stephen H. Wise, managing director of The Carlyle Group and PPD board member. "David is a proven leader whose deep industry knowledge and vision will enable PPD to further its partnerships with pharmaceutical and biotech companies around the globe."
Mr. Simmons said, "This is a remarkable opportunity to join and lead a world-class pharmaceutical services organization through its next phase of prosperity and expansion. As we work to extend PPD’s industry leadership position, we will maintain and strengthen PPD’s reputation for quality, innovation and integrity. I look forward to working with PPD’s seasoned leadership team and exceptional employees worldwide. Together, we will continue to grow the company and deliver quality results for clients and stakeholders."
Allen R. Thorpe, managing director of Hellman & Friedman LLC and PPD board member, said, "David’s wealth of pharmaceutical industry and international experience, combined with his well-honed leadership skills, will power PPD to meet the evolving needs of its clients. David is a client-focused leader with a keen understanding of the challenges and opportunities facing the biopharmaceutical industry. Working with PPD’s strong leadership team and talented employees, David will enhance PPD’s impressive credentials as an industry leader."
Mr. Simmons joins PPD following 15 years with Pfizer in several senior roles. In his most recent position, Mr. Simmons was the president and general manager of the emerging markets and established products business units. These business units represent approximately $18.5 billion of Pfizer’s annual revenue. In addition to these business units, his duties also included responsibility for the biosimilar development program. Prior to this role, Mr. Simmons held various positions of increasing responsibility in information technology and pharmaceutical operations, including roles in several countries around the world.
Mr. Simmons earned his degree in applied mathematics and industrial management from Carnegie-Mellon University.
PPD is owned by global alternative asset manager The Carlyle Group and private equity firm Hellman & Friedman, which jointly purchased PPD in December 2011.